8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 22, 2026·SEC
Material company update
Mar 10, 2026·SEC
Tenax Therapeutics, Inc.(TENX)Earnings, Financials & Key Ratios
TENX•NASDAQ
Price updated Jun 19, 2026
AboutTenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.Show more
- Revenue$0
- EBITDA-$56M-220.8%
- Net Income-$53M-198.8%
- EPS (Diluted)-1.34-16.5%
- ROE-55.64%-58.2%
TENX Key Insights
Tenax Therapeutics, Inc. (TENX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 39.8% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TENX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TENX Price & Volume
Tenax Therapeutics, Inc. (TENX) stock price & volume — 10-year historical chart
Loading chart...
TENX Growth Metrics
Tenax Therapeutics, Inc. (TENX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-139.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM43.15%
Return on Capital
10 Years-195.19%
5 Years-270.34%
3 Years-89.72%
Last Year-59.65%
TENX Recent Earnings
Tenax Therapeutics, Inc. (TENX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.35+12.5%
$0.40
Rev
—
—
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.38+69.8%
$1.26
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.40+69.9%
$1.33
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.27+46.0%
$0.50
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.35vs $0.40+12.5% | — |
| Q2 2026 | Mar 10, 2026 | $0.38vs $1.26+69.8% | — |
| Q4 2025 | Nov 12, 2025 | $0.40vs $1.33+69.9% | — |
| Q3 2025 | Aug 13, 2025 | $0.27vs $0.50+46.0% | — |
Based on last 12 quarters of dataView full earnings history →
TENX Peer Comparison
Tenax Therapeutics, Inc. (TENX) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATHA | 17.12M | 4.34 | -0.17 | -381.01% | 0.03 | |||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PRTA | 467.51M | 8.93 | -1.97 | -92.84% | -260.92% | -49.88% | 0.05 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 MDGL | 11.66B | 505.75 | -39.36 | 432.05% | -27.32% | -50.15% | 0.59 | |
 ESPR | 654.91M | 3.15 | -28.64 | 21.31% | -1.77% | |||
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 |
Compare TENX vs Peers
Tenax Therapeutics, Inc. (TENX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TENX Income Statement
Tenax Therapeutics, Inc. (TENX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 13.62K | 9.02K | 0 | 114.75K | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -13.62K▲ 0% | -9.02K▲ 33.8% | 0▲ 100.0% | -114.75K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | 28.13% | 33.82% | 100% | - | 100% | - | - | - | - | - |
Operating Expenses | 9.21M | 6.89M | 8.56M | 9.75M | 32.73M | 11.05M | 8.23M | 19.49M | 56.38M | 61.62M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 5.68M | 5.65M | 5.08M | 5.19M | 7.58M | 5.68M | 5M | 6.79M | 23.71M | 23.09M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 3.53M | 1.24M | 3.47M | 4.56M | 25.15M | 5.38M | 3.23M | 12.71M | 32.67M | 38.53M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -9.21M▲ 0% | -6.89M▲ 25.1% | -8.56M▼ 24.1% | -9.87M▼ 15.3% | -32.73M▼ 231.7% | -11.05M▲ 66.2% | -8.23M▲ 25.5% | -19.49M▼ 136.8% | -56.38M▼ 189.2% | -61.62M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | 82.52% | 25.12% | -24.11% | -15.34% | -231.66% | 66.23% | 25.5% | -136.75% | -189.24% | - |
EBITDA | -9.19M | -6.88M | -8.55M | -9.75M | -32.62M | -10.94M | -8.23M | -17.58M | -56.38M | -58.76M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | 82.53% | 25.11% | -24.2% | -14.07% | -234.45% | 66.46% | 24.8% | -113.7% | -220.75% | -142.87% |
D&A (Non-Cash Add-back) | 13.62K | 9.02K | 5.02K | 114.75K | 108.98K | 113.33K | 8K | 0 | 0 | 0 |
EBIT | -9.21M | -6.89M | -8.56M | -9.85M | -32.47M | -11.04M | -7.69M | -17.58M | -56.38M | -58.76M |
Net Interest Income | 0 | 0 | 144K | 29.37K | -949 | -4.44K | -23.97K | 1.89M | 3.82M | 3.75M |
Interest Income | 0 | 0 | 144K | 31K | 0 | 0 | 0 | 1.91M | 3.82M | 3.75M |
Interest Expense | 0 | 0 | 0 | 1.63K | 949 | 4.44K | 23.97K | 23K | 0 | 0 |
Other Income/Expense | 366.22K | 79.83K | 160.9K | 16.54K | 253.88K | 4.75K | 523K | 1.89M | 3.79M | 3.71M |
Pretax Income | -8.84M▲ 0% | -6.81M▲ 22.9% | -8.39M▼ 23.2% | -9.85M▼ 17.4% | -32.47M▼ 229.6% | -11.05M▲ 66.0% | -7.71M▲ 30.2% | -17.6M▼ 128.3% | -52.6M▼ 198.8% | -57.91M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -8.84M▲ 0% | -6.81M▲ 22.9% | -8.39M▼ 23.2% | -9.85M▼ 17.4% | -32.47M▼ 229.6% | -11.05M▲ 66.0% | -7.71M▲ 30.2% | -17.6M▼ 128.3% | -52.6M▼ 198.8% | -57.91M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | 79.88% | 22.92% | -23.2% | -17.36% | -229.64% | 65.98% | 30.2% | -128.27% | -198.82% | -139.18% |
Net Income (Continuing) | -8.84M | -6.81M | -8.39M | -9.85M | -32.47M | -11.05M | -7.71M | -17.6M | -52.6M | -57.91M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -10022.32▲ 0% | -7359.14▲ 26.6% | -26.60▲ 99.6% | -2125.38▼ 7890.2% | -2524.80▼ 18.8% | -600.80▲ 76.2% | -31.04▲ 94.8% | -1.15▲ 96.3% | -1.34▼ 16.5% | -1.28▲ 0% |
EPS Growth % | -1504.03% | 26.57% | 99.64% | -7890.15% | -18.79% | 76.2% | 94.83% | 96.3% | -16.52% | 43.15% |
EPS (Basic) | -10022.32 | -7359.14 | -26.60 | -2125.38 | -2524.80 | -600.80 | -31.09 | -1.15 | -1.34 | - |
Diluted Shares Outstanding | 915 | 915 | 3.87K | 4.63K | 12.86K | 18.39K | 248.45K | 15.27M | 39.22M | 45.23M |
Basic Shares Outstanding | 915 | 915 | 3.87K | 4.63K | 12.86K | 18.39K | 248K | 15.27M | 39.22M | 45.23M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TENX Balance Sheet
Tenax Therapeutics, Inc. (TENX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 8.06M | 13.32M | 6.18M | 6.8M | 5.69M | 3.21M | 11.68M | 96.69M | 104.23M | 123.18M |
Cash & Short-Term Investments | 7.73M | 12.86M | 5.4M | 6.71M | 5.58M | 2.12M | 9.79M | 94.85M | 97.56M | 118.75M |
Cash Only | 1.6M | 12.37M | 4.91M | 6.25M | 5.58M | 2.12M | 9.79M | 94.85M | 97.56M | 118.75M |
Short-Term Investments | 6.12M | 494.63K | 493.88K | 462.69K | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 50.17K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 345.86K | 251.58K | 64K | 6.66M | 4.42M |
Total Non-Current Assets | 1.83M | 16.96K | 184.44K | 73.19K | 303.24K | 196.24K | 1.12K | 0 | 0 | 0 |
Property, Plant & Equipment | 9.95K | 8.53K | 176.01K | 64.75K | 294.8K | 186.69K | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 1.81M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 8.44K | 8.44K | 8.44K | 8.44K | 8.44K | 9.55K | 1.12K | 0 | 0 | 0 |
Total Assets | 9.89M▲ 0% | 13.34M▲ 34.8% | 6.37M▼ 52.3% | 6.87M▲ 7.9% | 5.99M▼ 12.8% | 3.4M▼ 43.2% | 11.68M▲ 243.2% | 96.69M▲ 727.5% | 104.23M▲ 7.8% | 123.18M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -57.62% | 34.85% | -52.27% | 7.91% | -12.76% | -43.18% | 243.19% | 727.46% | 7.8% | 917.81% |
Total Current Liabilities | 1.01M | 1.57M | 2.53M | 2.12M | 1.56M | 1.85M | 3.59M | 4.69M | 7.16M | 8.49M |
Accounts Payable | 611.86K | 749.81K | 1.66M | 757.86K | 859.64K | 448.43K | 2.07M | 3.16M | 6.04M | 6.35M |
Days Payables Outstanding | 16.4K | 30.36K | - | 2.41K | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 120.49K | 0 | 624.3K | 500.9K | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 33.67K | 244.46K | 426.12K | 319.61K | 0 | 245.39K | 236.88K | 0 | 1.11M | 2.14M |
Current Ratio | 7.99x | 8.51x | 2.44x | 3.21x | 3.64x | 1.74x | 3.26x | 20.60x | 14.56x | 14.52x |
Quick Ratio | 7.99x | 8.51x | 2.44x | 3.21x | 3.64x | 1.74x | 3.26x | 20.60x | 14.56x | 14.52x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 60.38K | 124.17K | 183.59K | 64.2K | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 124.17K | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 60.38K | 0 | 183.59K | 64.2K | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.01M | 1.57M | 2.59M | 2.24M | 1.75M | 1.91M | 3.59M | 4.69M | 7.16M | 8.49M |
Total Debt | 0 | 0 | 171.73K | 305.04K | 290.78K | 807.89K | 500.9K | 0 | 0 | 0 |
Net Debt | -1.6M | -12.37M | -4.73M | -5.95M | -5.29M | -1.32M | -9.29M | -94.85M | -97.56M | -118.75M |
Debt / Equity | - | - | 0.05x | 0.07x | 0.07x | 0.54x | 0.06x | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 2.02x |
Interest Coverage | - | - | - | -6053.94x | -34218.56x | -2485.58x | -320.73x | -764.30x | - | - |
Total Equity | 8.88M▲ 0% | 11.77M▲ 32.5% | 3.77M▼ 68.0% | 4.63M▲ 22.6% | 4.24M▼ 8.2% | 1.49M▼ 64.8% | 8.1M▲ 442.5% | 91.99M▲ 1036.0% | 97.07M▲ 5.5% | 114.69M▲ 0% |
Equity Growth % | -48.18% | 32.53% | -67.95% | 22.61% | -8.23% | -64.83% | 442.5% | 1035.98% | 5.52% | 1073.56% |
Book Value per Share | 9706.95 | 12865.06 | 974.30 | 997.96 | 330.07 | 81.17 | 32.59 | 6.02 | 2.48 | 2.54 |
Total Shareholders' Equity | 8.88M | 11.77M | 3.77M | 4.63M | 4.24M | 1.49M | 8.1M | 91.99M | 97.07M | 114.69M |
Common Stock | 141 | 379 | 674 | 1.26K | 2.52K | 4.58K | 30 | 0 | 1K | 2K |
Retained Earnings | -213.5M | -227.8M | -236.17M | -246.02M | -278.49M | -289.54M | -297.25M | -314.86M | -367.45M | -383.17M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -16.19K | 516 | 458 | -70 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TENX Cash Flow Statement
Tenax Therapeutics, Inc. (TENX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -12.14M | -5.5M | -7.56M | -9.27M | -10.86M | -12.01M | -5.9M | -14.81M | -35.8M | -38.14M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | 23.51% | 54.7% | -37.4% | -22.72% | -17.08% | -10.65% | 50.85% | -150.86% | -141.71% | -617.13% |
Net Income | -8.84M | -14.14M | -8.39M | -9.85M | -32.47M | -11.05M | -7.71M | -17.6M | -52.6M | -57.91M |
Depreciation & Amortization | 13.62K | 9.02K | 107.28K | 114.75K | 108.98K | 113.33K | 8K | 0 | 0 | 0 |
Stock-Based Compensation | 79.59K | 190.08K | 0 | 0 | 0 | 0 | 191K | 1.13M | 0 | -1.3M |
Deferred Taxes | -4.83K | 407.77K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 498.49K | 7.43M | 270.51K | 361.34K | 22.12M | 366.86K | 25K | 23K | 19.16M | -33.44M |
Working Capital Changes | -3.89M | 606.75K | 460.4K | 102.44K | -610.09K | -1.45M | 1.58M | 1.64M | -2.36M | 1.91M |
Change in Receivables | 1.11M | -122.61K | 0 | 698.37K | -22.5K | 0 | -306K | 58K | 0 | 0 |
Change in Inventory | 5M | -729.36K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -5M | 729.36K | 883.04K | 0 | 0 | -344.95K | 1.65M | 1.06M | 2.88M | 4.51M |
Cash from Investing | 3.75M | 7.35M | -1.65K | 20.11K | 452.61K | -2.32K | 3K | 0 | 0 | 0 |
Capital Expenditures | -4.54K | -7.59K | -3.57K | -3.49K | -5.25K | -2.32K | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 3.75K | 7.36K | 0 | 0 | 0 | 0 | 3K | 0 | 0 | 0 |
Cash from Financing | 498.49K | 8.91M | 96.5K | 10.6M | 9.74M | 8.55M | 13.57M | 99.87M | 38.51M | 45.45M |
Debt Issued (Net) | 0 | 0 | 0 | 244.66K | 0 | 624.3K | -624K | -501K | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 96.5K | 8.66M | 9.19M | 7.93M | 0 | 0 | 38.51M | 45.45M |
Dividends Paid | 0 | -7.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -498.49K | 16.24M | 0 | 1.69M | 544.65K | 0 | 14.19M | 100.37M | 0 | 0 |
Net Change in Cash | -8.39M▲ 0% | 10.76M▲ 228.3% | -7.46M▼ 169.3% | 1.34M▲ 118.0% | -666.32K▼ 149.6% | -3.46M▼ 419.3% | 7.67M▲ 321.6% | 85.06M▲ 1009.3% | 2.71M▼ 96.8% | 7.31M▲ 0% |
Free Cash Flow | -12.15M▲ 0% | -5.51M▲ 54.7% | -7.56M▼ 37.3% | -9.28M▼ 22.7% | -10.86M▼ 17.1% | -12.02M▼ 10.6% | -5.9M▲ 50.9% | -14.81M▼ 150.9% | -35.8M▼ 141.7% | -38.14M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | 23.49% | 54.66% | -37.27% | -22.71% | -17.09% | -10.62% | 50.86% | -150.86% | -141.71% | -129.6% |
FCF per Share | -13273.28 | -6018.64 | -1952.41 | -2001.37 | -844.59 | -653.32 | -23.76 | -0.97 | -0.91 | -0.84 |
FCF Conversion (FCF/Net Income) | 1.37x | 0.81x | 0.90x | 0.94x | 0.33x | 1.09x | 0.77x | 0.84x | 0.68x | 0.66x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 24K | 23K | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TENX Key Ratios
Tenax Therapeutics, Inc. (TENX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -67.94% | -65.98% | -108.01% | -234.61% | -732.21% | -385.12% | -160.8% | -35.17% | -55.64% | -56.32% |
Return on Invested Capital (ROIC) | -95.75% | -154.76% | - | - | - | - | - | - | - | 1877.32% |
Debt / Equity | - | - | 0.05x | 0.07x | 0.07x | 0.54x | 0.06x | - | - | 0.00x |
Interest Coverage | - | - | - | -6053.94x | -34218.56x | -2485.58x | -320.73x | -764.30x | - | - |
FCF Conversion | 1.37x | 0.81x | 0.90x | 0.94x | 0.33x | 1.09x | 0.77x | 0.84x | 0.68x | 0.66x |
Related:TENX Dividend History·TENX Revenue History·TENX Price History·TENX P/E History·TENX Financial Ratios·TENX Institutional Holders
TENX SEC Filings & Documents
Tenax Therapeutics, Inc. (TENX) SEC filings — annual & quarterly reports (10-K, 10-Q)
TENX Frequently Asked Questions
Tenax Therapeutics, Inc. (TENX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tenax Therapeutics, Inc. (TENX) grew revenue by 0.0% over the past year. Growth has been modest.
Tenax Therapeutics, Inc. (TENX) reported a net loss of $57.9M for fiscal year 2025.
Dividend & Returns
Tenax Therapeutics, Inc. (TENX) has a return on equity (ROE) of -55.6%. Negative ROE indicates the company is unprofitable.
Tenax Therapeutics, Inc. (TENX) had negative free cash flow of $38.1M in fiscal year 2025, likely due to heavy capital investments.